Paul Hagopian, Chief Growth Officer, Fingerpaint Group
Advertisement
Articles by Paul Hagopian, Chief Growth Officer, Fingerpaint Group
Advertisement
Latest Updated Articles
- The opportunity to evolve the oncology model is ready and waiting
Published: June 1st 2023 | Updated: June 29th 2023
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms
2
Pharmaceutical Executive Daily: FDA Approves Hernexeos
3
FDA Approves Dupixent as First Treatment for Allergic Fungal Rhinosinusitis in Adults and Children
4
FDA Approves Hernexeos Under National Priority Voucher Program
5